Connect with us

Biotech

Heuristik Opens its Capital to Make the Leap to Europe and the U.S.

Heuristik has already committed the support of two business angels of Spanish origin, whose names have not been disclosed. In addition, the company is currently negotiating with other funds of Spanish, Portuguese, and U.S. origin. Even so, the company’s intention is for the lead investor in the round to be from the United States, but it values “positively” the presence of Spanish capital.

Published

on

Heuristik is expanding with its sights set on Europe. The Spanish company has opened a financing round of half a million euros that aims to expand its business in the European Union (EU) area, according to Antxon Caballero, CEO of the company.

Heuristik has developed proprietary software that combines fingerprint recognition with Artificial Intelligence (AI). This software solution is designed to manage patient portfolio data, but also foresees the possibility of managing information related to healthcare workers.

The company’s main objective is to speed up the identification of patients in medical emergencies, post-operative situations, and health centers, getting involved in any situation where users are unconscious, without documentation or with any communication problems.

Find more details about Heuristik and its plans to expand its business to Europe and the United States and find the most important business headlines of the day with the Born2Invest mobile app.

Heuristik has confirmed the support of two business angels of Spanish origin, whose names have not been disclosed

Heuristik has already committed the support of two business angels of Spanish origin, whose names have not been disclosed. In addition, the company is currently negotiating with other funds of Spanish, Portuguese, and U.S. origin. Even so, the company’s intention is for the lead investor in the round to be from the United States, but it values “positively” the presence of Spanish capital due to its extensive experience in the healthcare sector.

Although the main objective for 2022 is to enter various European hospitals, the company intends to land in the United States in mid-2023. Precisely, the current conversations with investors located in Boston and New York are due to the company’s willingness to cross the pond in the coming months. In addition, the company claims to be working on new solutions that connect users’ healthcare information, linking patient data with the aim of improving efficiency in healthcare centers, hospitals or companies dedicated to healthcare.

SEE ALSO  US stock exchange welcomes recreational marijuana investors

The company has fifteen employees spread throughout Spain, located in Barcelona, Madrid, Valladolid, and the Basque Country

Currently, Heuristik, based in Bilbao, has fifteen employees spread throughout Spain, located in Barcelona, Madrid, Valladolid and the Basque Country. For the coming year, the company’s intention is to exceed twenty employees, once the investment round has been closed.

To take the step and reach European operators in 2022, the company also plans to receive a Horizon Europe grant, the European Union (EU) Research and Innovation (R&I) framework program for 2021-2027. The initiative is intended to support European projects from the conceptual phase to market introduction.

__

(Featured image by 401(K)2012 CC BY-SA 2.0 via Flickr)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.